# Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

> **NCT01520870** · PHASE2 · COMPLETED · sponsor: **Grupo Español de Investigación en Neurooncología** · enrollment: 49 (actual)

## Conditions studied

- Glioblastoma
- Brain Tumor, Recurrent

## Interventions

- **DRUG:** PF-299804 (Dacomitinib)

## Key facts

- **NCT ID:** NCT01520870
- **Lead sponsor:** Grupo Español de Investigación en Neurooncología
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2015-04
- **Final completion:** 2017-03-09
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2021-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520870, "Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01520870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*